Topics
July/August 2025 | Guest Editor's Page
A Hopeful Future for Patients with IRDs
Ben Shaberman, MA, MS
May 4, 2026
Johnson & Johnson Showcases New Vision Research at ARVO 2026
Lineage Cell Therapeutics Reports 36-Month Data for OpRegen in Geographic Atrophy
Atsena Therapeutics Reports Positive 6-Month Data from LIGHTHOUSE Trial of ATSN-201 in XLRS
May 1, 2026
Astellas Showcases New Geographic Atrophy Research at ARVO 2026
April 2026 Insert
Editorially independent supported by Abbvie and Regenxbio
April 2026 Supplement
Editorially independent content supported with advertising by EyePoint
Free Print Subscription
Email Newsletter
Conference Calendar